Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

por Chrispijn, Melissa, Drenth, Joost PH
Publicado 2011

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?

por Betzel, Bark, Drenth, Joost PH
Publicado 2014

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management

por Cnossen, Wybrich R, Drenth, Joost PH
Publicado 2014

Loss to follow‐up in the hepatitis C care cascade: A substantial problem but opportunity for micro‐elimination

por van Dijk, Marleen, Drenth, Joost P.H.
Publicado 2020

Prevention of overuse: A view on upper gastrointestinal endoscopy

por de Jong, Judith J, Lantinga, Marten A, Drenth, Joost PH
Publicado 2019

Why zolpidem increases the risk of falls and fractures in patients with cirrhosis

por Weersink, Rianne Antoinet, Drenth, Joost P.H., Borgsteede, Sander Diederik
Publicado 2022

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

por Gevers, Tom JG, Chrispijn, Melissa, Wetzels, Jack FM, Drenth, Joost PH
Publicado 2012

Legal and Ethical Challenges in Developing a Dutch Nationwide Hepatitis C Retrieval Project (CELINE)

por van Dijk, Marleen, van Agt, Frans M., Drenth, Joost P.H.
Publicado 2020

Gastroparesis in patients with inactive Crohn's disease: a case series

por Kristinsson, Jón O, Hopman, Wim PM, Oyen, Wim JG, Drenth, Joost PH
Publicado 2007

Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia

por Samuels, Mark E, te Morsche, Rene HM, Lynch, Mary E, Drenth, Joost PH
Publicado 2008

Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial

por Wijnands, Titus FM, Gevers, Tom JG, Kool, Leo J Schultze, Drenth, Joost PH
Publicado 2015

Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study

por Kok, Karin F, te Morsche, René H, van Oijen, Martijn GH, Drenth, Joost PH
Publicado 2010

Guidance for Safety and Dosing of Medicines in Patients With Cirrhosis Is Available

por Weersink, Rianne A., Drenth, Joost P.H., Hunfeld, Nicole G.M., Borgsteede, Sander D.
Publicado 2019

Concomitant Intake of Coca‐Cola to Manage the Drug–Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers

por van Seyen, Minou, Colbers, Angela, Abbink, Evertine J., Drenth, Joost P.H., Burger, David M.
Publicado 2019

Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience

por Pape, Simon, Nevens, Frederik, Verslype, Chris, Mertens, Caroline, Drenth, Joost P.H., Tjwa, Eric T.T.L.
Publicado 2020

NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects

por Jansen, Jos C., Wolthuis, David, Van Scherpenzeel, Monique, Ratziu, Vlad, Drenth, Joost P.H., Lefeber, Dirk J.
Publicado 2018

Risk–efficacy balance of ulipristal acetate compared to surgical alternatives

por Middelkoop, Mei‐An, Bet, Pierre M., Drenth, Joost P.H., Huirne, Judith A.F., Hehenkamp, Wouter J.K.
Publicado 2021

Tamoxifen for the treatment of polycystic liver disease: A case report

por Aapkes, Sophie E., Bernts, Lucas H.P., van den Berg, M., Gansevoort, Ron T., Drenth, Joost P.H.
Publicado 2021

Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life

por Duijzer, Renée, Barten, Thijs R.M., Staring, Christian B., Drenth, Joost P.H., Gevers, Tom J.G.
Publicado 2022

Impact of liver volume on polycystic liver disease-related symptoms and quality of life

por Neijenhuis, Myrte K, Kievit, Wietske, Verheesen, Stef MH, D’Agnolo, Hedwig M, Gevers, Tom JG, Drenth, Joost PH
Publicado 2017